A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs Alisertib (Primary) ; Paclitaxel
- Indications Bladder cancer; Renal cancer
- Focus Therapeutic Use
- 07 Mar 2018 Status changed from not yet recruiting to completed.
- 02 Jun 2014 The trial protocol presented at 50th Annual Meeting of the American Society of Clinical Oncology.
- 14 Apr 2014 New trial record